---
layout: post
title: "科伦药业：琥珀酸曲格列汀片获药品注册批准"
date: 2022-03-11 15:50:21 +0800
categories: cailianshe
tags: 财联社新闻
---
<p style="display:none;height:1px;overflow:hidden;"><br /></p><!-- EM_StockImg_Start --><p style="text-align:center;"><a href="http://quote.eastmoney.com/unify/r/0.002422" data-code="002422|0|2" data-code2="002422|0|6|" class="EmImageRemark" target="_blank"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=0.002422&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 002422_0" data-code="K 002422|0|2" data-code2="K 002422|0|6|" style="border:#d1d1d1 1px solid;" width="578" height="276" /></a></p><!-- EM_StockImg_End --><p>科伦药业公告，公司琥珀酸曲格列汀片获得药品注册批准。琥珀酸曲格列汀片为武田开发的长效二肽基肽酶-4(DPP-4)抑制剂，用于2型糖尿病成人患者改善血糖控制。 <br /></p><p class="em_media">（文章来源：财联社）</p>

<http://finews.zning.xyz/html_News/NewsShare.html?infoCode=NW202203112306344312>

[返回财联社新闻](//finews.withounder.com/category/cailianshe.html)｜[返回首页](//finews.withounder.com/)